BEDMINSTER, N.J. and DUBLIN, Ireland, May 30, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that Gwen Fisher has joined the company in a newly created role as vice president of Corporate Communications.
In this role, Fisher will be responsible for leading internal and external communications for the company. Specifically, she is charged with advancing and implementing an integrated, progressive corporate communications strategy designed to educate key stakeholders about the company and its lead product, Vascepa®.
“Gwen’s deep experience in communications within the pharmaceutical and biotech industry, across multiple stakeholder groups and at evolving companies, makes her an ideal fit for Amarin, especially as we ramp up preparations for the launch of an anticipated expanded indication for Vascepa,” said John F. Thero, president and chief executive officer of Amarin. “We are delighted to have her join our growing team.”
Fisher brings more than 25 years of experience as a business leader and communications expert, having served in a variety of leadership positions with Shire, Pfizer, Wyeth and Merck. Her last position with Shire was heading Global Portfolio Communications, where she was responsible for internal and external communications for the global commercial and R&D organizations.
“I’m thrilled to be joining an exciting company like Amarin to lead the Communications function at such a critical time in the Company’s growth and transformation,” Fisher said. “The medical need in the cardiovascular space is great, so I look forward to collaborating with my new colleagues to educate stakeholders about the tremendous value Amarin has to offer patients in this therapeutic area.”
Fisher earned her B.A. in Public Relations from Washington State University’s Edward R. Murrow College of Communications; and an MBA from University of California, Los Angeles, Anderson School of Management.
About Amarin
Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in polyunsaturated fatty acids and lipid science. Vascepa (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription in the United States, Lebanon and the United Arab Emirates. Amarin’s commercial partners are pursuing additional regulatory approvals for Vascepa in Canada, China and the Middle East. For more information about Amarin, visit www.amarincorp.com.
